Delving into the Latest Updates on Ipragliflozin L-Proline with Synapse

The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is ≥ 7.5% with sulfonylurea and metformin, 2) to investigate changes of other metabolic and cardiovascular risk factors such as triglyceride, HDL-cholesterol, uric acid, blood pressure, and inflammatory markers, 3) to examine changes of body composition including fat and muscle mass with volume status.

Start Date25 Apr 2017

Sponsor / Collaborator

Seoul National University Bundang Hospital

[+1]

100 Clinical Results associated with Ipragliflozin L-Proline

Login to view more data

100 Translational Medicine associated with Ipragliflozin L-Proline

Login to view more data

100 Patents (Medical) associated with Ipragliflozin L-Proline

Login to view more data

303

Literatures (Medical) associated with Ipragliflozin L-Proline

01 Dec 2024·International Journal of Biological Macromolecules

Drug repurposing: An antidiabetic drug Ipragliflozin as Mycobacterium tuberculosis sirtuin-like protein inhibitor that synergizes with anti-tuberculosis drug isoniazid

Article

Author: Yan, Yaru ; Zhang, Jinghan ; Huang, Tingting ; Xie, Jianping ; Xie, Longxiang ; Zhang, Chao ; Yan, Shuangquan ; Zhen, Junfeng ; Huang, Hairong

The surge of drug-resistant Mycobacterium tuberculosis (DR-TB) impedes the World Health Organization's efforts in ending TB and calls for new therapeutic formulations. M. tuberculosis sirtuin-like protein Rv1151c is a bifunctional enzyme with both deacetylation and desuccinylation activities, which plays an important role in M. tuberculosis drug resistance and stress responses. Thus, it appears to be a promising target for the development of new TB therapeutics. In this study, we screened 31,057 ligand compounds from seven compound libraries in silico to identify inhibitors of Rv1151c. Ipragliflozin can bind to Rv1151c and interact stably. Ipragliflozin can change the acylation level of M. tuberculosis by inhibiting Rv1151c and effectively inhibit the growth of M. tuberculosis H37Rv and M. smegmatis. It can potentiate the first-front anti-TB drug isoniazid. As an antidiabetic drug, Ipragliflozin can be potentially included in the regimen to treat diabetes-tuberculosis comorbidity.

01 Nov 2024·Hypertension Research

Water and sodium conservation response induced by SGLT2 inhibitor ipragliflozin in Dahl salt-sensitive hypertensive rats

Article

Author: Masuda, Takahiro ; Onaka, Tatsushi ; Yoshida, Masahide ; Nagata, Daisuke

Sodium-glucose cotransporter 2 (SGLT2) inhibitors increase urine volume with glucosuria and natriuresis. We recently reported that osmotic diuresis by the SGLT2 inhibitor ipragliflozin induces fluid homeostatic action via the stimulation of fluid intake and vasopressin-induced water reabsorption in euvolemic rats. However, the effects of SGLT2 inhibitors on these parameters in hypervolemic animals remain unclear. In this study, Dahl salt-sensitive hypertensive rats, a hypervolemic rat model, were fed a low-salt (0.3%) or high-salt (8%) diet for 14 days, then divided into vehicle or ipragliflozin (0.01%) groups. During 7 days of treatment, the high-salt diet groups significantly increased fluid intake and urine volume. In the ipragliflozin groups, fluid intake and urine volume increased by 63% and 235%, respectively, in rats fed a normal-salt diet and by 46% and 72%, respectively, in rats fed a high-salt diet. Ipragliflozin increased urinary vasopressin by 200% and solute-free water reabsorption by 196% in the normal-salt group but by only 44% and 38%, respectively, in the high-salt group. A high-salt diet significantly increased fluid balance (fluid intake - urine volume) and Na⁺ balance (Na⁺ intake - urinary Na⁺), but ipragliflozin did not change fluid and Na⁺ balance in normal- or high-salt groups. A high-salt diet significantly increased systolic blood pressure, but ipragliflozin did not significantly change systolic blood pressure in normal- or high-salt groups. In conclusion, SGLT2 inhibitor ipragliflozin did not change fluid and Na⁺ balance regardless of basal fluid retention, suggesting the potential of SGLT2 inhibitors to maintain body water and Na⁺.

01 Oct 2024·Journal of Cardiology

Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial

Article

Author: Ohte, Nobuyuki ; Imai, Takumi ; Node, Koichi ; Sata, Masataka ; Teragawa, Hiroki ; Doi, Masaru ; Yamada, Hirotsugu ; Kadokami, Toshiaki ; Ohishi, Mitsuru ; Kusunose, Kenya ; Fukumoto, Kazuo ; Tanaka, Atsushi ; Koide, Yuji

BACKGROUNDWe hypothesized that the beneficial effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on diastolic function might depend on baseline left ventricular (LV) systolic function.METHODSTo investigate the effects of SGLT2 inhibitors on LV diastolic function in patients with type 2 diabetes mellitus (T2DM), we conducted a post-hoc sub-study of the PROTECT trial, stratifying the data according to LV ejection fraction (LVEF) at baseline. After excluding patients without echocardiographic data at baseline or 24 months into the PROTECT trial, 31 and 38 patients with T2DM from the full analysis dataset of the PROTECT trial who received ipragliflozin or no SGLT2 inhibitor (control), respectively, were included. The primary endpoint was a comparison of the changes in echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels from baseline to 24 months between the two groups stratified according to baseline LVEF.RESULTSDifferences in diastolic functional parameters (e' and E/e') were noted between the two groups. Among the subgroups defined according to median LVEF values, those with higher LVEF (≥60 %) who received ipragliflozin appeared to have a higher e' and lower E/e' than did those who received the standard of care with no SGLT2 inhibitor, indicating longitudinal improvements between baseline and follow up (p = 0.001 and 0.016, respectively).CONCLUSIONSIpragliflozin generally improved LV diastolic function in patients with type 2 diabetes, the extent of this improvement might appear to vary with LV systolic function.

100 Deals associated with Ipragliflozin L-Proline

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10200	Ipragliflozin L-Proline	A10BK05	DB11698

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	JP	-	17 Jan 2014
Diabetes Mellitus, Type 2	JP	-	17 Jan 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	TW	Astellas Pharma, Inc.	28 Nov 2011
Liver Diseases	Phase 1	US	Astellas Pharma, Inc.	01 May 2010
Diabetes Mellitus, Type 2	Preclinical	TW	Astellas Pharma, Inc.	28 Nov 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IPRA-CKD (ADA2024)	Not Applicable	Diabetes Mellitus, Type 1 \| Chronic Kidney Diseases eGFR \| microalbuminuria \| HbA1c ... View more	-	Ipragliflozin	(lsqbcizpix) = ntmvvgmruf zvnsjyoihf (ytxywqfabg, -38.7 to 20.6)	Negative	14 Jun 2024
				Ipragliflozin (Control (CTRL))	(lsqbcizpix) = ugdkljxmyf zvnsjyoihf (ytxywqfabg, -34.0 to 22.9)
Suglat-AID (ADA2023)	Not Applicable	Diabetes Mellitus, Type 1	-	Ipragliflozin 50 mg	vfsujkqgtl(vqvyvvvahp) = sttwiwfivk dltuklvrzl (fbxtucssxx )	-	20 Jun 2023
JPRN-UMIN000015170 (EASD2022)	Not Applicable	HbA1c \| BMI \| visceral fat area ... View more	103	Ipragliflozin 50 mg	uqstblqtff(jhulggusln) = ojygczcsol kvdekhxwen (sqjogljsng )	Positive	20 Sep 2022
				Metformin 1000 mg	uqstblqtff(jhulggusln) = zbescwagln kvdekhxwen (sqjogljsng )
NCT02479399 (STELLA-LONG TERM, Pubmed)	Not Applicable	Diabetes Mellitus, Type 2 First line	11,412	ipragliflozin (Treatment-naïve patients)	(cvrvbxcgbc) = aiqdyucmzu xcbnynfnyp (tpyblknhrr ) View more	-	01 Oct 2021
				ipragliflozin (Non-naïve patients)	(cvrvbxcgbc) = vlzolojchn xcbnynfnyp (tpyblknhrr ) View more
NISM Study (ADA2021)	Not Applicable	-	87	Ipragliflozin	ejrrigabwj(xwvprvbptl) = idcwttmdfx jfkwfgfcyj (lyukqzrami ) View more	-	01 Jun 2021
				Sitagliptin	ejrrigabwj(xwvprvbptl) = fnpwfopsea jfkwfgfcyj (lyukqzrami ) View more
NCT02577003 \| NCT02564211 (Pubmed \| Diabetes Obes Metab)	Not Applicable	Diabetes Mellitus, Type 2	-	Ipragliflozin 50 mg	(fvjtlppbem) = qylicbklvk sqlfgzcban (axbczbcvqo )	-	25 May 2021
NCT02479399 (STELLA-LONG TERM, Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	11,412	Ipragliflozin in patients aged <65 years	grofohfjie(olckmzfipc) = hrodwhvjff ueocdunnow (qklokztyge ) View more	-	17 Mar 2021
				Ipragliflozin in patients aged ≥65 years	grofohfjie(olckmzfipc) = yqtoodzsaw ueocdunnow (qklokztyge ) View more
EASL2020	Not Applicable	Fibrosis, Liver \| Nonalcoholic Steatohepatitis hemoglobin A1c \| visceral fat area	-	Ipragliflozin (50 mg/day)	lfarvtvicw(iwvxnxnrzp) = kbagstuzwd msiwwkmihj (bpzxlpblng )	Positive	27 Aug 2020
				Active control treatment (excluding SGLT2, pioglitazone, and/or glucagon-like peptide-1 analogs)	lfarvtvicw(iwvxnxnrzp) = gxecmswxot msiwwkmihj (bpzxlpblng )
JPRN-jRCTs031180205 (ADA2020)	Not Applicable	Diabetes Mellitus, Type 2 Second line	-	Ipragliflozin	tdawzemuaf(cwvcrhuvwr) = hohuieboic znuajyzzas (jqjfmedjlv ) View more	-	01 Jun 2020
				Sitagliptin	tdawzemuaf(cwvcrhuvwr) = vcwpsvjbiw znuajyzzas (jqjfmedjlv ) View more
NCT01225081 \| NCT01071850 \| NCT01117584 \| NCT00621868 \| NCT01057628 \| NCT01135433 \| NCT01316094 \| NCT02452632 \| NCT01242215 \| NCT02175784 \| NCT01505426 \| NCT02794792 (Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	-	Ipragliflozin 50 mg	(wgtiewjxvs) = adtxalmvrz kjdzewekmh (auxehltzxx ) View more	-	01 Dec 2019
				Placebo	(wgtiewjxvs) = jvdtvicpqv kjdzewekmh (auxehltzxx ) View more